Division of Nutrition, St John's National Academy of Health Sciences, Bangalore, Karnataka, India.
Department of Biostatistics, St. John's Medical College and Hospital, Bangalore, Karnataka, India.
BMJ Open. 2021 May 6;11(5):e043644. doi: 10.1136/bmjopen-2020-043644.
We describe the rationale and broad study design of the Indian Diabetes and Metabolic Health (InDiMeT) study, a new prospective, observational study incorporating extensive epigenetic (DNA methylation) and lipidomic signatures to examine their association with the dysregulation of adipose de novo lipogenesis (DNL) in South Asian Indians. The InDiMeT study aims to use a case-control design to identify genetic and modifiable-environmental-lifestyle associated determinants of (1) epigenomic (DNA methylome) dysregulation of adipose DNL in type 2 diabetes mellitus (T2DM) adipose tissue, (2) identify correlates of epigenomic (DNA methylome) dysregulation of adipose DNL in peripheral blood mononuclear cells (PBMCs) from T2DM subjects and (3) elucidate plasma lipidomic correlates of adipose DNL in T2DM that can be used as biomarkers of adipose tissue dysfunction.
The InDiMeT study will involve recruitment of 176 normoglycaemic and T2DM individuals who will be undergoing laparoscopic surgery for clinical conditions. Extensive phenotyping of the subjects will be conducted and DNA methylome and lipidomic measurements will be made. The adipose DNL pathway genes are likely to be hypermethylated in patients with T2DM with corresponding reduction of gene expression. Correlates of epigenomic (DNA methylome) dysregulation of adipose DNL pathway in PBMCs and their adipose and plasma lipidomic signatures in T2DM subjects could act as early markers of development of T2DM.
For the InDiMeT study, ethical approval for addressing the specific aims has been obtained from the Institutional Ethics Committee, St John's Medical College and Hospital, St John's National Academy of Health Sciences, Bangalore. Findings from this study will be disseminated through scientific publications in peer-reviewed journals, research conferences and via presentations to stakeholders, patients, clinicians, public and policymakers through appropriate channels.
我们描述了印度糖尿病和代谢健康(InDiMeT)研究的基本原理和广泛的研究设计,这是一项新的前瞻性、观察性研究,纳入了广泛的表观遗传学(DNA 甲基化)和脂质组学特征,以研究它们与南亚印度人脂肪从头合成(DNL)失调的关系。InDiMeT 研究旨在采用病例对照设计,确定 2 型糖尿病(T2DM)脂肪组织中脂肪 DNL 的表观遗传学(DNA 甲基组)失调的遗传和可修改的环境-生活方式相关决定因素,(1)鉴定 T2DM 受试者外周血单核细胞(PBMCs)中脂肪 DNL 的表观遗传学(DNA 甲基组)失调的相关因素,(2)阐明 T2DM 中脂肪 DNL 的血浆脂质组学相关性,可作为脂肪组织功能障碍的生物标志物。
InDiMeT 研究将招募 176 名血糖正常和 T2DM 个体,他们将因临床情况接受腹腔镜手术。对受试者进行广泛的表型分析,并进行 DNA 甲基化组和脂质组学测量。T2DM 患者的脂肪 DNL 途径基因可能发生过度甲基化,相应的基因表达减少。T2DM 受试者 PBMCs 中脂肪 DNL 途径的表观遗传学(DNA 甲基化组)失调的相关因素及其脂肪和血浆脂质组学特征可能作为 T2DM 发展的早期标志物。
对于 InDiMeT 研究,已经从班加罗尔的圣约翰医学院和医院、圣约翰国家健康科学学院的机构伦理委员会获得了针对特定目标的伦理批准。本研究的结果将通过在同行评议期刊上发表科学出版物、研究会议以及通过适当的渠道向利益相关者、患者、临床医生、公众和政策制定者进行演讲来传播。